Press Release Archive
-
Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline
-
European Commission Approves VELCADE® As A Frontline Induction Therapy Before Stem Cell TransplantationDecision could significantly improve transplant outcomes for patients with multiple myeloma
-
STELARA® Receives CHMP Positive Opinion For Treatment Of Psoriatic ArthritisSTELARA Recommended for Approval in Adult Patients with Active Psoriatic Arthritis
-
New Data Confirms Circulating Tumor Cells Are Useful Predictors of Progression-free and Overall SurvivalFirst Study to Demonstrate Value of Circulating Tumor Cell Enumeration in Chinese Metastatic Breast Cancer Patients Published in Annals of Oncology
-
SIMPONI® ARIA™ (golimumab) for infusion Receives FDA Approval for TREATMENT OF MODERATELY TO SEVERELY ACTIVE Rheumatoid arthritisFirst Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis
-
Johnson & Johnson Reports 2013 Second-Quarter ResultsSales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;Second-Quarter EPS was $1.33Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*
-
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
-
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2013
-
New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell MalignanciesIf approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma
-
Johnson & Johnson Innovation Announces Finalists of Cognition Challenge$100,000 awarded for solutions addressing Alzheimer’s disease and cognitive disorders